DVAX
Price
$10.01
Change
+$0.17 (+1.73%)
Updated
Jun 3 closing price
Capitalization
1.62B
57 days until earnings call
ESPR
Price
$1.05
Change
+$0.13 (+14.13%)
Updated
Jun 3 closing price
Capitalization
495.94M
62 days until earnings call
Interact to see
Advertisement

DVAX vs ESPR

Header iconDVAX vs ESPR Comparison
Open Charts DVAX vs ESPRBanner chart's image
Dynavax Technologies
Price$10.01
Change+$0.17 (+1.73%)
Volume$1.73M
Capitalization1.62B
Esperion Therapeutics
Price$1.05
Change+$0.13 (+14.13%)
Volume$5.76M
Capitalization495.94M
DVAX vs ESPR Comparison Chart
Loading...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DVAX vs. ESPR commentary
Jun 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DVAX is a StrongBuy and ESPR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 04, 2025
Stock price -- (DVAX: $10.01 vs. ESPR: $1.05)
Brand notoriety: DVAX and ESPR are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: DVAX: 68% vs. ESPR: 100%
Market capitalization -- DVAX: $1.62B vs. ESPR: $495.94M
DVAX [@Pharmaceuticals: Other] is valued at $1.62B. ESPR’s [@Pharmaceuticals: Other] market capitalization is $495.94M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.74B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DVAX’s FA Score shows that 0 FA rating(s) are green whileESPR’s FA Score has 0 green FA rating(s).

  • DVAX’s FA Score: 0 green, 5 red.
  • ESPR’s FA Score: 0 green, 5 red.
According to our system of comparison, ESPR is a better buy in the long-term than DVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DVAX’s TA Score shows that 6 TA indicator(s) are bullish while ESPR’s TA Score has 5 bullish TA indicator(s).

  • DVAX’s TA Score: 6 bullish, 3 bearish.
  • ESPR’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, DVAX is a better buy in the short-term than ESPR.

Price Growth

DVAX (@Pharmaceuticals: Other) experienced а +2.35% price change this week, while ESPR (@Pharmaceuticals: Other) price change was +28.06% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +13.58%. For the same industry, the average monthly price growth was +15.20%, and the average quarterly price growth was +63.51%.

Reported Earning Dates

DVAX is expected to report earnings on Jul 31, 2025.

ESPR is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+13.58% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DVAX($1.62B) has a higher market cap than ESPR($496M). DVAX YTD gains are higher at: -21.613 vs. ESPR (-52.273). DVAX has higher annual earnings (EBITDA): 9.67M vs. ESPR (-150.11M). DVAX has more cash in the bank: 742M vs. ESPR (82.2M). DVAX (257M) and ESPR (266M) have identical debt. DVAX has higher revenues than ESPR: DVAX (232M) vs ESPR (116M).
DVAXESPRDVAX / ESPR
Capitalization1.62B496M327%
EBITDA9.67M-150.11M-6%
Gain YTD-21.613-52.27341%
P/E Ratio31.63N/A-
Revenue232M116M200%
Total Cash742M82.2M903%
Total Debt257M266M97%
FUNDAMENTALS RATINGS
DVAX vs ESPR: Fundamental Ratings
DVAX
ESPR
OUTLOOK RATING
1..100
5213
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
35
Fair valued
PROFIT vs RISK RATING
1..100
68100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8794
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ESPR's Valuation (35) in the Biotechnology industry is somewhat better than the same rating for DVAX (68). This means that ESPR’s stock grew somewhat faster than DVAX’s over the last 12 months.

DVAX's Profit vs Risk Rating (68) in the Biotechnology industry is in the same range as ESPR (100). This means that DVAX’s stock grew similarly to ESPR’s over the last 12 months.

DVAX's SMR Rating (100) in the Biotechnology industry is in the same range as ESPR (100). This means that DVAX’s stock grew similarly to ESPR’s over the last 12 months.

DVAX's Price Growth Rating (87) in the Biotechnology industry is in the same range as ESPR (94). This means that DVAX’s stock grew similarly to ESPR’s over the last 12 months.

DVAX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ESPR (100). This means that DVAX’s stock grew similarly to ESPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DVAXESPR
RSI
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
72%
Bearish Trend 3 days ago
89%
Momentum
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
81%
MACD
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
68%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 7 days ago
84%
Declines
ODDS (%)
Bearish Trend 8 days ago
80%
Bearish Trend 14 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
81%
Aroon
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PEPSX28.77N/A
N/A
Principal Glb Emerging Markets R5
TROSX14.54N/A
N/A
T. Rowe Price Overseas Stock
HLMRX19.12N/A
N/A
Harding Loevner Intl Small Coms Instl
ZVGNX52.29N/A
N/A
Zevenbergen Genea Investor
QRSIX39.50N/A
N/A
FPA Queens Road Small Cap Value Instl

DVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, DVAX has been loosely correlated with ACET. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if DVAX jumps, then ACET could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DVAX
1D Price
Change %
DVAX100%
+1.73%
ACET - DVAX
39%
Loosely correlated
+4.01%
SNDL - DVAX
35%
Loosely correlated
+0.79%
ALKS - DVAX
34%
Loosely correlated
-0.06%
SUPN - DVAX
33%
Loosely correlated
+1.00%
ESPR - DVAX
32%
Poorly correlated
+14.30%
More

ESPR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ESPR has been loosely correlated with ALKS. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ESPR jumps, then ALKS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESPR
1D Price
Change %
ESPR100%
+14.30%
ALKS - ESPR
34%
Loosely correlated
-0.06%
DVAX - ESPR
32%
Poorly correlated
+1.73%
ZOMDF - ESPR
26%
Poorly correlated
-5.38%
EVO - ESPR
26%
Poorly correlated
+1.26%
AMRX - ESPR
25%
Poorly correlated
+0.40%
More